Research: Advances in cell biology relevant to critical illness

Current Opinion in Critical Care

Volumn 10, Issue 4, 2004, Pages 279-291

  Fink, Mitchell P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

HIF 1; NF B; PARP 1; TLR4

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; RNA; TOLL LIKE RECEPTOR;

CELL ACTIVITY; CRITICAL ILLNESS; CYTOLOGY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MICROARRAY; EPITHELIUM; GENE SEQUENCE; GENE SILENCING; GENOME; HUMAN; HYPOXIA; IMMUNE RESPONSE; INFLAMMATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

CELL HYPOXIA; CRITICAL ILLNESS; EPITHELIUM; HUMANS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 3242794265     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccx.0000130150.33814.71     Document Type: Review

References (179)

1. Venter JC, Adams MD, Myers EW, et al.: The sequence of the human genome. Science 2001, 291:1304-1351.
2. International Human Genome Sequencing Consortium: initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
3. Schulze A, Downward J: Navigating gene expression using microarrays-a technology review. Nat Cell Biol 2001, 3:E190-E195.
4. Sali A, Glaeser R, Earnest T, et al.: From words to literature in structural proteomics. Nature 2003, 422:216-225.
5. Phizicky E, Bastiaens PIH, Zhu H, et al.: Protein analysis on a proteomic scale. Nature 2003, 422:208-215.
6. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
7. Fire A, Xu S, Montgomery MK, et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
8. ••] established that short sequences of double-stranded RNA can effectively silence the expression of genes in an efficient and highly selective manner.
9. ••].
10. Song E, Lee SK, Wang J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9:347-351.
11. Gay N, Keith F: Drosophila Toll and IL-1 receptor. Nature 1991, 351:355-356.
12. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
13. Lemaitre B, Nicolas E, Michaut L, et al.: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
14. Bowie A, O'Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukocyte Biol 2000, 67:508-514.
15. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol 2001, 2:675-680.
16. Wright SD, Ramos RA, Tobias PS, et al.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
17. Poltorak A, He X, Smirnova I, et al.: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088. This landmark paper identified TLR4 as mutated protein in C3H/HeJ mice and established the importance of this protein for activation of the innate immune response by LPS.
18. Hoshino K, Takeuchi O, Kawai T, et al.: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
19. Arbour NC, Lorenz E, Schutte BC, et al.: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
20. Shimazu R, Akashi S, Ogata H, et al.: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782.
21. Nagai Y, Akashi S, Nagafuku M, et al.: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002, 3:667-672.
22. Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappaB by a posttranslational mechanism. Cell 1986, 47:921-928.
23. Pahl HL: Activators and target genes of rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
24. Senftleben U, Karin M: The IKK/NF-κB pathway. Crit Care Med 2002, 30:S18-S26.
25. Bowie AG, Moynagh PN, O'Neill LAJ: Lipid peroxidation is involved in the activation of NF-κB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. J Biol Chem 1997, 272:25941-25950.
26. Baldwin AS: The NF-kappaB and I kappa B proteins: new discoveries and new insights. Annu Rev Immunol 1996, 14:649-683.
27. Malinin NL, Boldin MP, Kovalenko AV, et al.: MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
28. Zandi E, Karin M: Bridging the gap: composition, regulation, and physiological function of the IB kinase complex. Mol Cell Biol 1999, 19:4547-4551.
29. Lee FS, Hagler J, Chen ZJ, et al.: Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997, 88:213-222.
30. Marinari B, Constanzo A, Viola A, et al.: Vav cooperates with CD28 to induce NF-kappaB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur J Immunol 2002, 32:447-456.
31. Baumann B, Weber CK, Troppmair J, et al.: Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation, Proc Natl Acad Sci U S A 2000, 97:4615-4620.
32. Takahashi N, Tetsuka T, Uranishi H, et al.: Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur J Biochem 2002, 269:4559-4565.
33. Okazaki T, Sakon S, Sasazuki T, et al.: Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Comm. 2003, 300:807-812.
34. Wang D, Westerheide SD, Hanson JL, et al.: Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000, 275:32592-32597.
35. •] provide evidence that activation of NF-κB is likely to be a key factor leading to mortality in patients with severe sepsis.
36. •].
37. Fink MP, Heard SO: Research review: laboratory models of sepsis and septic shock. J Surg Res 1990, 49:186-196,
38. Sheehan M, Wong HR, Hake PW, et al.: Parthenolide, an inhibitor of the nuclear factor-kappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002, 61:953-963.
39. Altavilla D, Squadrito G, Minutoli L, et al.: Inhibition of nuclear factor-kappaB activation by IRFI 042, protects against endotoxin-induced shock. Cardiovasc Res 2002, 54:684-693.
40. Sheehan M, Wong HR, Hake PW, et al.: Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res 2002, 82:99-107.
41. Haudek SB, Spencer E, Bryant DD, et al.: Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 2001, 280:H962-H968.
42. Ulloa L, Ochani M, Yang H, et al.: Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002, 99:12351-12356. This study showed that treatment of mice with ethyl pyruvate, starting as late as 24 hours after the onset infection, rescues mice from lethal sepsis.
43. Sappington PL, Han X, Yang R, et al.: Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated Caco-2 enterocytic monolayers. J Pharmacol Exp Ther 2003, 304:464-476. This combination of in vitro and in vivo experiments showed that ethyl pyruvate is capable of preventing intestinal epithelial dysfunction induced by inflammatory mediators.
44. Bagby GJ, Plessala KJ, Wilson LA, et al.: Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis models of sepsis. J Infect Dis 1991, 163:83-88.
45. Remick D, Manohar P, Bolgos G, et al.: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995, 4:89-95.
46. Echtenacher B, Falk W, Mannel DN, et al.: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990, 145:3762-3766.
47. Joshi AR, Chung CS, Song GY, et al.: NF-kappaB activation has tissue-specific effects on immune cell apoptosis during polymicrobial sepsis. Shock 2002, 18:380-386.
48. Gjertsson I, Hultgren OH, Collins LV, et al.: Impact of transcription factors AP-1 and NF-kappaB on the outcome of experimental Staphylococcus aureus arthritis and sepsis. Microbes Infect 2001, 3:527-534.
49. Ulloa L, Fink MP, Tracey KJ: Ethyl pyruvate protects against lethal systemic inflammation by preventing HMGB1 release. Ann N Y Acad Sci 2003, 987:319-321.
50. Arbabi S, Maier RV: Mitogen-activated protein kinases. Crit Care Med 2002, 30:S74-S79.
51. Garrington TP, Johnson GI: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999, 11:211-218.
52. 2-terminal kinases. J Biol Chem 1999, 274:16604-16610.
53. Rana A, Gallo K, Godowski P, et al.: The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. J Biol Chem 1996, 271:19025-19028.
54. Saitoh M, Nishitoh H, Fujii M, et al.: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1999, 17:2596-2606.
55. Rouse J, Cohen P, Trigon S, et al.: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994, 78:1027-1037.
56. Fuchs SY, Tappin I, Ronai Z: Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 2000, 275:12560-12564.
57. Nick JA, Avdi NJ, Gerwins P, et al.: Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J Immunol 1996, 156:4867-4875.
58. Baldassare JJ, Bi Y, Bellone CJ: The role of p38 mitogen-activated protein kinase in IL-1β transcription. J Immunol 1999, 162:5367-5373.
59. Raingeaud J, Gupta S, Rogers JS, et al.: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426.
60. Carl VS, Brown-Steinke K, Nicklin MJ, et al.: Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J Biol Chem 2002, 277:17448-17456.
61. Winston BW, Chan ED, Johnson GL, et al.: Activation of p38mapk, MKK3, and MKK4 by TNF-alpha in mouse bone marrow-derived macrophages. J Immunol 1997, 159:4491-4497.
62. Hashimoto S, Gon Y, Matsumoto K, et al.: N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br J Pharmacol 2001, 132:270-276.
63. Suzuki K, Hino M, Kutsuna H, et al.: Selective activation of p38 mitogen-activated protein kinase cascade in human neutrophils stimulated by IL-1 beta. J Immunol 2001, 167:5940-5947.
64. Young PR, McLaughlin MM, Kumar S, et al.: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997, 272:12116-12121.
65. Lee JC, Laydon JT, McDonnell PC, et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746. This study used a pharmacologic approach to identify p38 MAPK as a key protein in the transduction of proinflammatory signals in macrophages.
66. Prichett W, Hand A, Sheilds J, et al.: Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha. J Inflammation 1995, 45:97-105.
67. Young P, McDonnell P, Dunnington D, et al.: Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993, 39:C67-C69.
68. Kotlyarov A, Neininger A, Schubert C, et al.: MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nature Cell Biol 1999, 1:94-97.
69. Brook M, Sully G, Clark AR, et al.: Regulation of tumour necrosis factor mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett 2000, 483:57-61.
70. Guan Z, Buckman SY, Pentland AP, et al.: Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem 1998, 273:12901-12908.
71. Song GY, Chung CS, Jarrar D, et al.: Evolution of an immune suppressive macrophage phenotype as a product of p38 MAPK activation in polymicrobial sepsis. Shock 2000, 15:42-48.
72. Song GY, Chung CS, Chaudry IH, et al.: MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol 2001, 281:C662-C669.
73. Peng T, Lu X, Lei M, et al.: Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res 2003, 59:893-900.
74. Arcaroli J, Yum HK, Kupfner J, et al.: Role of p38 MAP kinase in the development of acute lung injury. Clin Immunol 2001, 101:211-219.
75. Fink MP: Cytopathic hypoxia in sepsis. Acta Anaesthesiol Scand 1997, 41(suppl 100):87-95.
76. Fink MP: Cytopathic hypoxia: mitochondrial dysfunction as a mechanism contributing to organ dysfunction in sepsis. Crit Care Clin North Am 2001, 17:219-237.
77. Bankey PE, Hill S, Geldon D: Sequential insult enhances liver macrophage-signaled hepatocyte dysfunction. J Surg Res 1994, 57:185-191.
78. Zingarelli B, Day BJ, Crapo JD, et al.: The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock. Br J Pharmacol 1997, 120:259-267.
79. Unno N, Wang H, Menconi MJ, et al.: Inhibition of inducible nitric oxide synthase ameliorates lipopolysaccharide-induced gut mucosal barrier dysfunction in rats. Gastroenterology 1997, 113:1246-1257. This study provided some of the earliest evidence that endotoxemia is associated with an acquired defect in mitochondrial function in intestinal epithelial cells.
80. Gross SS, Levi R: Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1992, 267:25722-25729.
81. Kantrow SP, Taylor DE, Carraway MS, et al.: Oxidative metabolism in rat hepatocytes and mitochondria during sepsis. Arch Biochem Biophys 1997, 345:278-288. This study was among the first to provide direct evidence that hepatic mitochondrial oxygen utilization is impaired in animals with sepsis.
82. King CJ, Tytgat S, Delude RL, et al.: Ileal mucosal oxygen consumption is decreased in endotoxemic rats but is restored toward normal by treatment with aminoguanidine. Crit Care Med 1999, 27:2518-2524. This study was among the first to provide direct evidence that intestinal epithelial mitochondrial oxygen utilization is impaired in animals with systemic inflammation induced by LPS administration.
83. Chen HW, Hsu C, Lu TS, et al.: Heat shock pretreatment prevents cardiac mitochondrial dysfunction during sepsis. Shock 2003, 20:274-279.
84. Brealey D, Brand M, Hargreaves I, et al.: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360:219-223. This landmark study provided the first solid evidence that mitochondrial dysfunction occurs in patients with sepsis and that impaired mitochondrial function in this setting may have prognostic implications.
85. Borutaité V, Brown GC: Rapid reduction of nitric oxide by mitochondria, and reversible inhibition of mitochondrial respiration by nitric oxide. Biochem J 1996, 315:295-299.
86. Cassina A, Radi R: Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996, 328:309-316.
87. Takehara Y, Kanno T, Yoshioka T, et al.: Oxygen-dependent regulation of mitochondrial energy metabolism by nitric oxide. Arch Biochem Biophys 1995, 323:27-32.
88. Nishikawa M, Sato EF, Kuroki T, et al.: Role of glutathione and nitric oxide in the energy metabolism of rat liver mitochondria. FEBS Lett 1997, 415:341-345.
89. Torres J, Darley-Usmer V, Wilson MT: Inhibition of cytochrome c oxidase in turnover by nitric oxide: mechanism and implications for control of respiration. Biochem J 1995, 312:169-173.
90. Giuffre A, Sarti P, D'Itri E, et al.: On the mechanism of inhibition of cytochrome c oxidase by nitric oxide. J Biol Chem 2000, 271:33404-33408.
91. Brown GC, Bolanos JP, Heales SJ, et al.: Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration. Neurosci Lett 1995, 193:201-204.
92. Wink DA, Mitchell JB: Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 1998, 25:434-456.
93. Pryor WA, Squadrito GL: The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 1995, 268:L699-L722.
94. Squadrito GL, Pryor WA: Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic Biol Med 1998, 25:392-403.
95. Radi R, Peluffo G, Alvarez MN, et al.: Unraveling peroxynitrite formation in biological systems. Free Radical Biol Med 2001, 30:463-488.
96. Du G, Mouithys-Mickalad A, Sluse FE: Generation of superoxide anion by mitochondria and impairment of their functions during anoxia and reoxygenation in vitro. Free Radical Biol Med 1998, 25:1066-1074.
97. Poderoso JJ, Carreras MC, Lisdero C, et al.: Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 1996, 328:85-92.
98. Ghafourifar P, Richter C: Nitric oxide synthase activity in mitochondria. FEBS Lett 1997, 418:291-296.
99. Kanai AJ, Pearce LL, Clemens PR, et al.: Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc Natl Acad Sci U S A 2001, 98:14126-14131.
100. Ghafourifar P, Schenk U, Klein SD, et al.: Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. J Biol Chem 1999, 27:31185-31188.
101. Lacza Z, Puskar M, Figueroa JP, et al.: Mitochondrial nitric oxide synthase is constitutively active and is functionally upregulated by hypoxia. Free Radic Biol Med 2001, 31:1605-1615.
102. Elfering SL, Sarkela TM, Giulivi C: Biochemistry of mitochondrial nitric-oxide synthase. J Biol Chem 2002, 277:38079-38086.
103. Packer MA, Porteous CM, Murphy MP: Superoxide production by mitochondria in the presence of nitric oxide forms peroxynitrite. Biochem Mol Biol Int 1996, 40:527-534.
104. Jekabsone A, Ivanoviene L, Brown GC, et al.: Nitric oxide and calcium together inactivate mitochondrial complex I and induce cytochrome c release. J Mol Cell Cardiol 2003, 35:803-809.
105. Brookes PS, Darley-Usmar V: Role of calcium and superoxide dismutase in sensitizing mitochondria to peroxynitrite-induced permeability transition. Am J Physiol Heart Circ Physiol 2004, 286:H39-H46.
106. Radi R, Rodriguez M, Castro L, et al.: Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys 1994, 308:96-102.
107. Castro L, Rodriguez M, Radi R: Aconitase is readily inactivated by peroxynitrite, but not its precursor, nitric oxide. J Biol Chem 1994, 269:29409-29415.
108. Boczkowski J, Lisdero C, Lanone S, et al.: Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm during endotoxemia. FASEB J 1999, 13:1637-1646.
109. Durkacz BW, Omidiji O, Gray DA, et al.: (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
110. Saitoh MS, Poirier GG, Lindahl T: Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry (Mosc) 1994, 33:7099-7106.
111. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, et al.: Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Mol Cell Biochem 1999, 193:137-148.
112. Du L, Zhang X, Han YY, et al.: Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 2003, 278:18426-18433.
113. Lautier D, Lageux J, Thibodeau J, et al.: Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem 1993, 122:171-193.
114. D'Amours D, Desnoyers S, D'Silva I, et al.: Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999, 342:249-268.
115. Ame JC, Jacobson EL, Jacobson MK: Molecular heterogeneity and regulation of poly(ADP-ribose) glycohydrolase. Mol Cell Biochem 1999, 193:75-81.
116. Schraufstatter IU, Hinshaw DB, Hyslop PA, et al.: Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 1986, 77:1312-1320.
117. Schraufstatter IU, Hyslop PA, Hinshaw DB, et al.: Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 1986, 83:4908-4912.
118. --induced DNA damage, PARP activation, and cellular energetic failure.
119. ••].
120. ••].
121. + contributes to impaired cellular respiration in immunostimulated enterocyte-like cells.
122. Pulido EJ, Shames BD, Selzman CH, et al.: Inhibition of PARS attenuates endotoxin-induced dysfunction of pulmonary vasorelaxation. Am J Physiol 1999, 277:L769-L776.
123. Szabo A, Salzman AL, Szabo C: Poly (ADP-ribose) synthetase activation mediates pulmonary microvascular and intestinal mucosal dysfunction in endotoxin shock. Life Sci 1998, 63:2133-2139.
124. Kuhnle S, Nicotera P, Wendel A, et al.: Prevention of endotoxin-induced lethality, but not of liver apoptosis in poly(ADP-ribose) polymerase-deficient mice. Biochem Biophys Res Comm 1999, 263:433-438.
125. Oliver FJ, Menissier-de Murcia J, Nacci C, et al.: Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999, 18:4446-4454.
126. Goldfarb RD, Marton A, Szabo E, et al.: Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 2002, 30:974-980.
127. Boulos M, Astiz ME, Barua RS, et al.: Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Crit Care Med 2003, 31:353-358.
128. Hassa PO, Covic M, Hasan S, et al.: The enzymatic and DNA binding activity of PARP-1 are not required for NF-κB coactivator function. J Biol Chem 2001, 276:45588-45597.
129. Ullrich O, Diestel A, Eyupoglu IY, et al.: Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 2001, 3:1035-1042.
130. Hassa PO, Buerki C, Lombardi C, et al.: Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol Chem 2003, 278:45145-45153.
131. Chang W-J, Alvarez-Gonzalez R: The sequence-specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J Biol Chem 2001, 276:47664.
132. Du X, Matsumura T, Edelstein D, et al.: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003, 112:1049-1057.
133. Akman HO, Zhang H, Siddiqui MA, et al.: Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells. Blood 2001, 98:3324-3331.
134. Peng JL, Zhang L, Drysdale L, et al.: The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A 2000, 97:8386-8391.
135. 2 hemostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578.
136. Semenza GL: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002, 64:993-998.
137. Wang GL, Jiang BH, Rue EA, et al.: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995, 92:5510-5514. This was a critical early paper from the Semenza laboratory at the Johns Hopkins University School of Medicine that led to recognition of HIF-1 as a key transcription factor in adaptive responses to hypoxia.
138. Kallio PJ, Wilson WJ, O'Brien S, et al.: Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999, 274:6525.
139. Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 2002, 272:22642-22647.
140. ••] provided important insights into the ways that cells sense changes in oxygen tension and translate this information into signals mediated by the HIF-1 pathway.
141. ••].
142. ••].
143. Bagby GJ, Lang CH, Giaimo ME, et al.: Increased glucose metabolism by epitrochlearis muscle removed from endotoxin-treated rats. Circ Shock 1986, 20:171-179.
144. L'Her E, Sebert P: A global approach to energy metabolism in an experimental model of sepsis. Am J Respir Crit Care Med 2001, 164:1444-1447.
145. Benigni F, Atsumi T, Calandra T, et al.: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000, 106:1291-1300.
146. Albina JE, Mastrofancesco B: Modulation of glucose metabolism in macrophages by products of nitric oxide synthase. Am J Physiol 1993, 264:C1594-C1599.
147. Mateo RB, Reichner JS, Mastrofancesco B, et al.: Impact of nitric oxide on macrophage glucose metabolism and glyceraldehyde-3-phosphate dehydrogenase activity. Am J Physiol 1995, 268:C669-C675.
148. El Awad BB, Kreft BB, Wolber EM, et al.: Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000, 58:43-50.
149. Haddad JJ, Land SC: A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1 alpha. FEBS Lett 2001, 505:274.
150. Sandau KB, Zhou J, Kietzmann T, et al.: Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 2001, 276:39805-39811.
151. Thornton RD, Lane P, Borghaei RC, et al.: Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2001, 350:307-312.
152. Hellwig-Burgel T, Rutkowski E, Metzen E, et al.: Interleukin-1 beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999, 94:1567.
153. Scharte M, Han X, Bertges DJ, et al.: Cytokines induce HIF-1 DNA binding and the expression of HIF-1-dependent genes in cultured rat enterocytes. Am J Physiol Gastrointest Liver Physiol 2003, 284:G373-G384.
154. Jung YJ, Isaacs JS, Lee S, et al.: IL-1 beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003, 17:2115-2117.
155. Ben-Av P, Crofford LJ, Wilder RL, et al.: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372:83-87.
156. Frank S, Hubner G, Breier G, et al.: Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995, 270:12607-12613.
157. Stevenson BR: Understanding tight junction clinical physiology at the molecular level. J Clin Invest 1999, 104:3-4.
158. Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2:285-293.
159. Tsukita S, Furuse M: The structure and function of claudins, cell adhesion molecules at tight junctions. Ann N Y Acad Sci 2000, 915:129-135.
160. Furuse M, Itoh M, Hirase T, et al.: Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin in tight junctions. J Cell Biol 1994, 127:1617-1626.
161. Fanning AS, Jameson BJ, Jesaitis LA, et al.: The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 1998, 273:29745-29753.
162. Itoh M, Nagafuchi A, Moroi S: Involvement of ZO-1 in cadherin-based cell adhesion through its direct binding to alpha catenin and actin filaments. J Cell Biol 1997, 138:181-192.
163. Sheth B, Fesenko I, Collins JE, et al.: Tight junction assembly during mouse blastocyst formation is regulated by late expression of ZO-1 alpha+ isoform. Development 1997, 124:2027-2037.
164. Sheth B, Moran B, Anderson JM, et al.: Post-translational control of occludin membrane assembly in mouse trophectoderm: a mechanism to regulate timing of tight junction biogenesis and blastocyst formation. Development 2000, 127:831-840.
165. Chavez A, Menconi MJ, Hodin RA, et al.: Cytokine-induced epithelial hyperpermeability: role of nitric oxide. Crit Care Med 1999, 27:2246-2251.
166. Unno N, Hodin RA, Fink MP: Acidic conditions exacerbate interferon-gamma-induced intestinal epithelial hyperpermeability: role of peroxynitrous acid. Crit Care Med 1999, 27:1429-1436.
167. Unno N, Menconi MJ, Smith M, et al.: Nitric oxide mediates interferon-gamma-induced hyperpermeability in cultured human intestinal epithelial monolayers. Crit Care Med 1995, 23:1170-1176.
168. •-dependent and independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock 2003, 19:229-237.
169. Adams RB, Planchon SM, Roche JK: IFN-y modulation of epithelial barrier function: time course, reversibility, and site of cytokine binding. J Immunol 1993, 150:2356-2363.
170. Planchon SM, Martins CAP, Guerrant RL, et al.: Regulation of intestinal epithelial barrier function by TGF-β1. Evidence for its role in abrogating the effects of T cell cytokine. J Immunol 1994, 153:5730-5739.
171. Madara JL, Stafford J: Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 1989, 83:724-727.
172. Salzman AL, Menconi MJ, Unno N, et al.: Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers. Am J Physiol 1995, 268:G361-G373. This was the first study to show that NO causes marked alterations in the barrier function of intestinal epithelial monolayers.
173. - rather than NO as such was responsible for epithelial barrier dysfunction induced by NO donors.
174. Chavez A, Morin MJ, Unno N, et al.: Acquired interferon-γ responsiveness during Caco-2 cell differentiation: effects on iNOS gene expression. Gut 1999, 44:659-665.
175. Unno N, Menconi MJ, Smith M, et al.: Hyperpermeability of intestinal epithelial monolayers is induced by NO: effect of low extracellular pH. Am J Physiol 1997, 272:G923-G934.
176. ••] (also by Han et al.) provide convincing evidence that endotoxemia is associated with epithelial barrier dysfunction in multiple organs. These studies provide evidence that altered barrier function is attributable to marked alterations in the expression
177. ••].
178. ••].
179. -.